Differences

This shows you the differences between two versions of the page.

--- pharmaceutical_companies:tekmira_pharmaceuticals [2023/06/01 20:56]
liam [Lipid nanoparticles]
+++ pharmaceutical_companies:tekmira_pharmaceuticals [2023/09/04 20:00] (current)
liam
@@ Line 23: / Line 23: @@
 The case between Tekmira and Alnylam was settled in November 2012, resulting in a restructured licensing agreement allowing Alnylam to resume using Tekmira’s LNP patents under terms with new “clarity.”((//Tekmira and Alnylam restructure relationship and settle all litigation.// (2012, November 12). U.S. Securities and Exchange Commission. https://web.archive.org/web/20220322141914/https://www.sec.gov/Archives/edgar/data/1447028/000117184312004102/newsrelease.htm)) This also allowed Acuitas to acquire a sublicense for some of the LNP technology from Tekmira - and conversely, Tekmira to use Acuitas’ RNAi tech - an arrangement which went into effect in December 2013.((George, J. (2017, February 10). //Doylestown biopharm firm granted injunction over licensing dispute.// American City Business Journals. https://web.archive.org/web/20170214043742/http://www.bizjournals.com/philadelphia/news/2017/02/10/arbutus-biopharma-abus-injunction-acuitus-sales.html))
-On December 19, 2014, Tekmira announced the appointment of [[:Richard Henriques, Jr.]] to the company's board of directors.((Rezler, J. P. (2014, December 19). //Tekmira Pharmaceuticals Announces Leadership Changes.// Securities and Exchange Commission. http://archive.today/2023.06.01-185035/https://www.sec.gov/Archives/edgar/data/1447028/000117184314005977/newsrelease.htm)) Henriques had previously served as Chief Financial Officer for the [[:Bill & Melinda Gates Foundation]].
+On December 19, 2014, Tekmira announced the appointment of [[:Richard Henriques]] to the company's board of directors.((Rezler, J. P. (2014, December 19). //Tekmira Pharmaceuticals Announces Leadership Changes.// Securities and Exchange Commission. http://archive.today/2023.06.01-185035/https://www.sec.gov/Archives/edgar/data/1447028/000117184314005977/newsrelease.htm)) Henriques had previously served as Chief Financial Officer for the [[:Bill & Melinda Gates Foundation]] and held a leadership role at [[Merck]]. In the same press release, Tekmira announced that [[:Ian MacLachlan]] was to resign as Executive Vice President and Chief Technical Officer as of December 31, 2014.
 ==== Ebola ====
@@ Line 41: / Line 41: @@
 | [[:Keith Manchester]]  | Board member  | [[:QVT Financial]]  |
 | [[:Hector McKay-Dunn]]  | -  | [[:British Columbia Technology Industry Association]], [[:Life Sciences British Columbia]], [[:Innovate BC]], [[:Genome British Columbia]], [[:United Way British Columbia]], [[:Canadian Red Cross]]  |
+| [[:Ian MacLachlan]]  | Chief Technical Officer and Executive Vice President  | -  |
 | [[:Mark Murray]]  | Chief Executive Officer  | [[:Crohn's & Colitis Foundation]]  |
 | [[:Michael Sofia]]  | -  | [[Gilead Sciences]], [[:International Society for Antiviral Research]], [[:Drexel University]]  |
@@ Line 48: / Line 49: @@
 ===== External links =====
+  * [[https://covidtruthinitiative.ca/en/Organizations/Tekmira-Pharmaceuticals|COVID Truth Initiative]]
 ==== Further reading ====
   * [[https://liamsturgess.substack.com/p/follow-the-patents-lipid-nanoparticles|Follow the Patents: Lipid Nanoparticles and COVID-19 Genetic Vaccines]] by [[:Liam Sturgess]]